Engineered Immune Progenitors Enable Scalable CAR-M Cancer Therapy
TL;DR Summary
Researchers engineered macrophage progenitor cells to self-renew and differentiate into macrophages for CAR-M therapy. Using GMPs, they produced a persistent immune cell supply that spread through the body in mice and slowed both blood cancers and solid tumors, offering a scalable alternative to CAR-T for broader cancer immunotherapy.
- Scientists Just Unlocked an Endless Army of Cancer-Fighting Cells ScienceAlert
- USC scientists just unlocked an endless supply of cancer-fighting immune cells ScienceDaily
- Scientists at USC have figured out how to create an army of cells to fight cancer ThePrint
- Progenitor Cells Self-Renew in Lab, Breaking Macrophage Therapy Supply Barrier Tech Times
- A new technique could keep cancer-fighting cells coming Tech Explorist
Reading Insights
Total Reads
1
Unique Readers
6
Time Saved
6 min
vs 6 min read
Condensed
96%
1,183 → 48 words
Want the full story? Read the original article
Read on ScienceAlert